Brinzolamide Eye Drop – (Nano suspension 1% w/v)
The Nano emulsion developed by Murli Krishna Pharma ensures the following:
- Nano particle based matrix, which can deliver hydrophilic as well as hydrophobic drugs using a combination of hydrophilic and hydrophobic excipients as a clear solution. This cogent use of excipients ensures that the drug is absorbed optimally and the Nano particles ensure that the drug penetrates not only through the hydrophobic and hydrophilic channels but also through the OraSerrata, which protects the eye from any foreign body entering the optical cavity.
- The protein binding is minimized due to encapsulation.
- The particle size is to the tune of 100 nm which makes the product easily sterile filterable.
- The formulation is in form of a clear solution and is available in the same concentration as the innovator i.e. 10 mg/ml. The product can be offered as a solution that can be sterile filtered and filled.
- We offer development services in case of a requirement for different formulation/dosage/strength
- Offer complete technical package for registrations in all regulated/semi regulated markets
- Products protected by ongoing Patents are not offered by MKPPL.
Additional information
| Documentation Available: | DMF in CTD Format |
|---|---|
| Dosage Form | Nano particles (for Ophthalmic suspensions) |
| Dosage Strength | 1% w/v |
Description
Problems Faced in Formulating Ophthalmic Delivery Systems
The cell structures act as semi permeable paracellular passive diffusion barriers or gates to large and hydrophilic solutes.
Small, lipophilic essential nutrients and toxic metabolites are delivered or removed, respectively, through passive or active
site-specific transcellular carrier-mediated influx or efflux transporters. Several retinal disorders are accompanied by dysfunction or breakdown of this BRB and their associated cell-cell signaling mechanisms.
The static morphologic structure responsible for all these organ-specific barriers is the tight junction (TJ).
Counter intuitively, curative drug therapy to these protected sites requires that drugs circumvent these naturally protective barriers.
Approach towards Developing Nanoparticles for Ophthalmic Products
Ophthalmic preparations have an inherent problem of poor bioavailability. The reason is that most ophthalmic preparations are based on an aqueous matrix. Use of an aqueous vehicle with particle has an issue with respect to permeation, as the key absorption site is the cornea, which is hydrophobic while the conjunctiva is hydrophilic. The absorption through the conjunctiva is impaired due to a protective layer known as Ora Serrata.
